The purpose of the Carmelina Study is to look at the impact of an investigational drug called linagliptin on the long-term occurrence of selected complications of cardiovascular disease (e.g. stroke or heart attack) in people with type 2 diabetes receiving standard of care
You may be eligible to take part in the Carmelina Study if:
You may be eligible to participate in this study if you:
Has your doctor recommended that you begin taking insulin to control your diabetes?
If so, you may want to consider participating in Achieve Control……
Achieve Control is a real-world study sponsored by Sanofi and will include patients who are starting insulin for the first time. The study will evaluate how well patient reach their HbA1C targets using one of the marketed basal insulin without experiencing symptoms of low blood sugar such as dizziness etc.
You may be eligible if ……
Your participation in this study is voluntary and will last up to 12 months if you complete the study. The cost for the insulin and supplies will be provided by the study sponsor.
Are you tired of daily injections to control your type 2 diabetes?
This is a clinical research study looking at a potential new treatment approach for people with type 2 diabetes. The approach uses a small investigational device to release exenatide, the active ingredient in another approved medication, to help control your blood sugar levels over a period of up to 6 months, without the need for daily liraglutide (also known as Victoza®) injections.
Can you take part in the FREEDOM-3S Study?
You may be eligible to take part if you:
DS8500-A-U202 Diabetic Trial
The DS8500-A-U202 Study is a clinical research study looking at safety and effectiveness of a potential new treatment option for people with type 2 diabetes who are receiving metformin.
You may be able to take part in the study if you:
If you are eligible and choose to take part, you will be in the study for up to 18 weeks and will have about 8 visits at the study center. There will be no cost to you to participate.
Sorella 2 is a study comparing a follow-on injectable rapid-acting recombinant insulin analog to insulin lispro (Humalog®) in adult patients with type 2 diabetes also using insulin glargine (Lantus®).
You may be able to take part in the study if you are already treated with insulin glargine and Humalog or Novolog at least 3 times daily before each meal in the last 6 months.
If you currently have an abnormal lipid profile, you may qualify to participate in a clinical research study. To qualify, you must be at least 18 years of age, have triglyceride levels between 200 and 500 mg/dL, and meet other eligibility criteria. Study-related exams and medication/placebo may be provided to qualified participants.
Do you have high cholesterol and a history of Heart Disease, Kidney Disease, or Diabetes? If so you may qualify for a clinical research study.
You may qualify for this study if you:
Clinical Research doctors are studying an investigational vaginal ring for birth control. Doctors are conducting this study to evaluate whether the investigational vaginal ring is safe and effective.
Do I qualify?
The study staff will determine if you are eligible to participate. At a minimum, you must meet the following criteria:
If you’ve had flu symptoms for less than 5 days, consider our study on a new investigational flu treatment.
Our clinic is looking for volunteers to test a new investigational study medication for people with influenza (flu). To participate you must:
Your medical history and other criteria will be reviewed at the first study visit to see if you can be in the study.
The main part of the study includes 4 visits to the study clinic over 7 days and 6 scheduled telephone calls over the next 3 months. Qualified participants will receive study medication at no cost.